Cleerly LABS vs Zio AT ECG Monitoring System

Cleerly LABS offers a focused, interactive web-based platform with 3D visualization for clinicians to analyze complex CCTA data and integrate into existing hospital workflows. While Zio AT provides a comprehensive solution for both patients and clinicians, Cleerly's dedicated platform for complex image analysis is highly optimized for its specific clinical user group, offering a streamlined diagnostic experience.

Both tools are FDA-cleared and offer high clinical value in cardiology. Cleerly LABS provides a unique, proactive approach by precisely characterizing coronary plaque and assessing ischemia from CCTA, which is crucial for preventing future cardiac events and personalizing treatment strategies. This focus on the underlying pathology of heart attacks and its potential to guide preventative interventions gives it a slight edge in foundational clinical impact compared to Zio AT's arrhythmia detection.

Cleerly LABS offers transparent, publicly disclosed pricing on a 'per analysis' basis, allowing for clearer financial planning despite the potential for out-of-pocket costs. In contrast, Zio AT's pricing is not publicly disclosed, requiring direct contact for details, which makes it difficult for potential customers to assess costs upfront and compare value effectively.

Both tools demonstrate strong enterprise readiness with cloud-based deployments, FDA clearance, HIPAA compliance, and BAAs. However, Cleerly LABS explicitly details its integration capabilities with PACS, RIS, and EHR via a dedicated on-site proxy, indicating a more robust and defined strategy for seamless integration into existing hospital and radiology workflows.

Both tools are highly innovative, leveraging AI to advance cardiac diagnostics. Cleerly LABS introduces a paradigm shift by providing detailed, quantitative characterization of coronary plaque from CCTA, moving beyond traditional lumen stenosis assessment to address the root cause of heart attacks and enable personalized preventive strategies. This proactive disease characterization represents a more fundamental innovation in cardiovascular disease management.

Zio AT provides publicly accessible 'Instructions for Use' and 'Clinical Reference Manuals' for its devices and software, along with dedicated support for various aspects including billing, and comprehensive FAQs for both patients and professionals. Cleerly offers support during business hours with after-hours priority, but its public documentation is less detailed. Zio AT's more extensive and publicly available documentation, coupled with specialized 24/7/365 support for billing, suggests a more comprehensive and accessible support infrastructure.